paper
provid
overview
current
global
market
manufactur
landscap
hydroxychloroquin
hcq
capac
capabl
global
produc
meet
potenti
demand
treat
patient
inflict
novel
corona
viru
hcq
efficaci
establish
definit
clinic
trial
also
assess
given
larg
exist
manufactur
base
abund
raw
materi
hcq
suppli
challeng
met
consider
effort
intern
cooper
preemptiv
coordin
emerg
effort
among
global
govern
regulatori
agenc
chemic
pharmaceut
industri
imper
meet
surg
demand
pandem
caus
novel
corona
viru
list
biggest
challeng
human
be
ever
face
modern
histori
effect
mean
viral
diseas
like
also
one
impact
human
invent
ie
vaccin
take
month
year
develop
prove
safe
efficaci
clinic
trial
among
option
readili
avail
health
care
provid
treat
highli
contagi
deadli
diseas
repurpos
exist
drug
especi
drug
expos
divers
patient
popul
known
accept
safeti
outcom
hydroxychloroquin
sulfat
hcq
figur
front
runner
fit
profil
indic
sever
preliminari
clinic
trial
especi
combin
azithromycin
efficaci
hcq
still
need
prove
larger
random
control
clinic
trial
rct
sever
underway
demand
hcq
alreadi
skyrocket
recent
week
due
part
surpris
virul
diseas
yearn
cure
populac
highli
visibl
endors
propel
sever
state
pharmaci
chain
unit
state
implement
alloc
program
measur
curb
hoard
product
j
u
r
n
l
p
r
e
p
r
f
ensur
steadi
albeit
limit
suppli
chain
physician
also
urg
prescrib
medicin
prophylact
use
sinc
mani
patient
reli
drug
treat
debilit
chronic
diseas
includ
rheumatoid
arthriti
ra
system
lupu
erythematosu
sle
meanwhil
sever
manufactur
respond
either
pledg
donat
substanti
number
tablet
promis
ramp
product
march
us
fda
issu
emerg
use
author
eua
permit
emerg
use
hydroxychloroquin
sulfat
hcq
older
chemic
cousin
chloroquin
di
phosphat
cq
suppli
strateg
nation
stockpil
treat
adult
adolesc
weigh
kg
hospit
clinic
trial
avail
particip
feasibl
clinic
justifi
current
shortag
hcq
acut
situat
could
either
allevi
increas
global
product
exacerb
escal
demand
especi
hcq
efficaci
treat
demonstr
unequivoc
rct
paper
focu
suppli
demand
hydroxychloroquin
origin
develop
treat
malaria
hydroxychloroquin
invent
alexand
r
surrey
sterl
drug
inc
new
york
gener
consid
less
toxic
better
toler
chloroquin
approv
us
ra
sle
addit
treatment
prophylaxi
malaria
show
figur
hcq
differ
cq
extra
hydroxyl
group
sulfat
salt
vs
diphosph
salt
cq
accord
variou
sourc
roughli
metric
ton
hcq
sulfat
sold
across
world
led
unit
state
account
quarter
amount
follow
india
china
consum
respect
figur
note
major
prescript
us
chronic
indic
ra
sle
fact
hcq
second
prescrib
medicin
ra
us
methotrex
revenu
hcq
sale
us
estim
well
million
annual
share
mostli
gener
drug
maker
includ
zydu
cadila
india
prasco
laboratori
ltd
india
sandoz
switzerland
teva
isreal
mylan
us
innov
brand
plaquenil
domin
european
japanes
market
sanofi
account
littl
us
manufactur
hcq
concentr
asia
europ
figur
data
difficult
verifi
rough
estim
would
put
india
lead
product
tonnag
follow
europ
china
howev
european
figur
might
includ
product
origin
made
india
india
undoubtedli
play
central
role
global
suppli
hcq
thank
burgeon
gener
drug
product
industri
estim
countri
produc
roughli
metric
ton
hcq
domest
market
domin
ipca
laboratori
ltd
market
share
similar
amount
export
led
zydu
cadila
ipca
also
world
lead
produc
chloroquin
di
phosphat
share
global
market
china
market
led
shanghai
pharma
share
countri
produc
roughli
metric
ton
hcq
domest
market
ton
export
mostli
variou
nonich
countri
china
drug
sold
tablet
us
film
coat
present
hcq
china
approv
us
fda
yet
follow
tabl
tabl
attempt
compar
hcq
market
prior
breakout
project
us
global
need
hcq
suppli
drug
inde
proven
efficaci
larger
definit
clinic
trial
assum
typic
regimen
would
includ
g
hcq
sulfat
tablet
note
current
worldwid
need
metric
ton
hcq
spread
across
entir
year
met
steadili
mostli
chronic
diseas
demand
howev
immedi
surg
exampl
us
popul
need
treatment
metric
ton
hcq
would
need
urgent
howev
us
popul
need
treat
metric
ton
hcq
would
need
week
global
treatment
rate
mean
requir
metric
ton
drug
week
time
current
world
annual
product
capac
withi
reasonabl
time
answer
question
let
examin
follow
develop
report
news
media
last
week
march
take
event
whole
face
valu
reason
expect
surg
metric
ton
billion
tablet
hcq
made
avail
within
month
two
larger
demand
howev
would
serious
challeng
global
manufactur
capac
capabl
ramp
product
signific
challeng
insurmount
follow
reason
hcq
formul
rel
straight
forward
drug
product
manufactur
generalpurpos
fillfinish
plant
suppli
api
met
ampl
capac
drug
product
manufactur
us
rest
world
repurpos
ramp
hcq
tablet
product
manufactur
process
hcq
api
hydroxychloroquin
sulfat
consid
averag
overal
complex
compar
market
small
molecul
therapeut
drug
fact
origin
procedur
make
hcq
disclos
inventor
surrey
still
practic
major
api
supplier
variant
improv
notwithstand
compound
made
step
abund
petroleum
feed
stock
benzen
ethylen
propylen
commod
chemic
histor
price
hcq
api
product
cycl
time
start
finish
rang
month
one
year
new
facil
gener
take
year
build
qualifi
high
degre
homolog
manufactur
process
well
chemic
composit
chloroquin
hydroxychloroquin
figur
suppli
chain
manufactur
site
interconvert
suit
chang
demand
analyt
control
end
product
product
process
straightforward
especi
compar
biolog
qualiti
pharmaceut
ca
nt
ensur
end
product
qualiti
control
alon
achiev
elabor
gmp
system
whole
product
process
includ
procur
raw
materi
process
valid
final
packag
j
u
r
n
l
p
r
e
p
r
f
shipment
recent
debacl
relat
person
protect
equip
like
face
mask
ventil
suppli
chain
testimoni
import
balanc
qualiti
rigor
suppli
speedi
emerg
situat
us
fda
exampl
issu
import
alert
ipca
laboratori
due
qualiti
problem
found
plant
howev
march
wake
surg
demand
hcq
cq
agenc
move
make
except
import
alert
three
ipca
facil
allow
firm
suppli
tablet
well
raw
materi
make
chloroquin
phosphat
hydroxychloroquin
sulphat
us
market
china
major
provid
raw
martial
make
hcq
api
insid
china
countri
spread
larg
contain
countri
plant
resum
normal
product
capac
surplu
api
capac
china
substanti
yet
tap
fulli
emerg
global
demand
india
capac
global
drug
suppli
import
current
trend
spread
countri
troubl
impact
current
futur
suppli
hcq
mani
essenti
drug
uncertain
countri
recent
ban
export
hcq
chloroquin
hope
decis
revers
domest
suppli
secur
grave
concern
also
prepared
servic
industri
play
vital
role
support
mani
multin
compani
viru
strike
care
nation
border
countri
govern
also
work
togeth
lower
bureaucrat
barrier
drug
suppli
ensur
qualiti
innov
effici
way
regulatori
bodi
work
togeth
find
creativ
solut
come
save
live
speed
matter
extrem
circumst
global
demand
surg
metric
ton
hcq
treat
world
popul
illustr
far
right
column
tabl
vital
necessari
close
intern
collabor
global
govern
pharmaceut
manufactur
regulatori
agenc
order
mobil
coordin
worldwid
resourc
meet
demand
lesson
learn
success
penicillin
product
scale
milligram
metric
ton
within
two
year
world
war
ii
achiev
leadership
account
courag
take
risk
cando
attitud
ingenu
scientist
engin
commit
govern
enthusiast
particip
privat
compani
refer
list
common
synthet
process
hydroxychloroquin
schemat
form
figur
illustr
hcq
activ
ingredi
prepar
rel
straightforward
manner
feedstock
includ
benzen
ethylen
acet
acid
butan
ethylen
ethanol
commod
chemic
abund
stabl
suppli
far
pharmaceut
manufactur
concern
mani
intermedi
within
scheme
also
enjoy
multipl
use
within
chemic
pharmaceut
industri
suppli
chain
rel
robust
unit
oper
consid
within
normal
rang
one
two
step
requir
high
temperatur
condit
cycl
time
regulatori
consider
critic
factor
bring
emerg
suppli
conclus
remain
cautious
optimist
global
manufactur
capabl
ramp
product
meet
demand
hcq
proven
efficaci
random
clinic
trial
ration
alloc
focu
resourc
j
u
r
n
l
p
r
e
p
r
f
truli
needi
vigor
implement
address
current
shortag
larg
suppli
catch
consid
signific
lead
time
ramp
product
scale
cost
api
product
rel
small
stare
materi
readili
avail
potenti
benefit
probabl
hcq
eventu
proven
efficaci
help
patient
inflict
immedi
ramp
product
risk
conting
definit
clinic
trial
conclud
appear
justifi
time
perspect
provid
two
pharmaceut
industri
veteran
current
global
market
hydroxychloroquin
drug
current
investig
treatment
patient
inflict
corona
viru
abil
manufactur
meet
potenti
surg
demand
delin
ampl
data
whether
hydroxychloroquin
ultim
efficaci
decid
larg
scale
control
clinic
trial
whether
drug
made
access
global
patient
need
requir
care
plan
global
govern
industri
leader
critic
time
hope
voic
heard
polici
maker
stakehold
alik
journal
preproof
